Real-Life Cefiderocol Use in Bone and Joint Infection: A French National Cohort
Ava Diarra1,2, Maxime Degrendel3, Isabelle Eberl4
1Department of Infectious Diseases, Hôpital Gustave Dron, 59200 Tourcoing, France.
Abstract:
Background: Cefiderocol (CFD) is a novel siderophore cephalosporin developed for the treatment of infections involving multidrug-resistant (MDR) Gram-negative bacilli (GNB) infections (1-3). For bone and joint infections (BJIs), the use of CFD is currently neither part of its market authorization nor recommended, and has not yet been assessed by large-scale studies. Objectives: To fill the scarcity of data regarding the use of CFD in BJIs, we aimed to describe patients' and infection characteristics along with the outcomes of the infection. Methods: We conducted a retrospective observational multicenter study in 22 French centers from January 2019 to December 2023. Results: From January 2019 to December 2023, 45 patients were included. Patients were mainly males (73%) with a median age of 62 years (interquartile range [IQR] 29), and a median Charlson comorbidity index of 3. Implant-related infections (20) were the most prominent, accounting for 44% of the cases. Carbapenemase-producing GNB were involved in 74% of the cases (n = 17/23), among which Pseudomonas aeruginosa accounted for 38% of these cases. Most patients received 6 g of CFD per day. CFD was used in combination with an antibiotic in 40 out of 45 cases (89%). The median duration of CFD treatment was 34 days. Seven patients (16%) experienced side effects, mainly gastro-intestinal disorders, including three (7%) who induced treatment cessation. Infection control included surgery in 37 (82%) patients. Failures and deaths occurred, respectively, in 22 (49%) and 10 (22%) cases. Conclusions: Our results suggest that CFD may be an alternative in MDR-GNB infections with limited therapeutic options.
Insights
Cefiderocol shows potential for treating multidrug-resistant Gram-negative bacilli bone and joint infections, though outcomes varied. Further research is needed to confirm its efficacy and safety in this patient population.
Area of Science:
- Infectious Diseases
- Pharmacology
- Orthopedics
Background:
- Cefiderocol (CFD) is a novel siderophore cephalosporin designed for multidrug-resistant Gram-negative bacilli (MDR-GNB) infections.
- Its use in bone and joint infections (BJIs) is not currently approved or widely studied, creating a data gap.
- This study addresses the need for data on CFD's application in BJIs.
Purpose of the Study:
- To describe patient and infection characteristics in BJIs treated with CFD.
- To evaluate the outcomes of CFD treatment for BJIs.
- To assess the safety and efficacy of cefiderocol in a real-world setting for BJIs.
Main Methods:
- Retrospective, observational, multicenter study conducted across 22 French centers.
- Data collected from January 2019 to December 2023.
- Inclusion of 45 patients with BJIs treated with cefiderocol.
Main Results:
- The study included 45 patients, predominantly males (73%), with a median age of 62.
- Implant-related infections were common (44%), often involving carbapenemase-producing GNB (74%), including Pseudomonas aeruginosa.
- CFD was administered at 6g/day, often in combination therapy (89%), with a median treatment duration of 34 days. Side effects were observed in 16% of patients. Infection control involved surgery in 82% of cases, with high rates of failure (49%) and mortality (22%).
Conclusions:
- Cefiderocol may serve as a viable therapeutic option for BJIs caused by MDR-GNB, especially when other treatments are limited.
- The study highlights the need for further investigation into optimal dosing and combination strategies.
- Clinical outcomes suggest a need for careful patient selection and monitoring when using CFD for BJIs.
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Acute Pyelonephritis II: Diagnostic Studies and Management
Antimicrobial Effectiveness
Staphylococcal Skin Infections
Inhibitors of Bacterial DNA Synthesis
Clinical Significance of Antibiotic Resistance


